Cargando…
HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption
Early-phase HIV remission (“cure”) trials aim to test interventions developed to eradicate HIV or to sustainably control HIV without antiretroviral treatment (ART). Many remission trials include analytic treatment interruption (ATI) to evaluate interventions, which increases the risk to participants...
Autores principales: | Okumu, Eunice Akinyi, Henderson, Gail E., Golin, Carol, Kuczynski, Kriste, Ormsby, Nuchanart Q., Peay, Holly L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319831/ https://www.ncbi.nlm.nih.gov/pubmed/37416088 http://dx.doi.org/10.1016/j.jve.2023.100331 |
Ejemplares similares
-
Corrigendum to “HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption” [J Virus Erad 9 (2) (June 2023) 100331]
por: Okumu, Eunice Akinyi, et al.
Publicado: (2023) -
Recommendations from Thai stakeholders about protecting HIV remission (‘cure’) trial participants: report from a participatory workshop
por: Peay, Holly L, et al.
Publicado: (2020) -
Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
por: Henderson, Gail E, et al.
Publicado: (2018) -
Corrigendum to ‘Decision making for invasive and non-invasive optional procedures within an acute HIV research cohort in Bangkok,’ [Contemporary Clinical Trials Communication (2023)101054]
por: Isaacson, Sinéad, et al.
Publicado: (2023) -
Decision making for invasive and non-invasive optional procedures within an acute HIV research cohort in Bangkok
por: Isaacson, Sinéad, et al.
Publicado: (2022)